BACKGROUND: Per current guidelines, patients with a first-degree relative (FDR) with adenomas should get screened at age 40. Data on the prevalence of adenomas and advanced adenomas (AAs) in these patients are lacking. OBJECTIVE: To examine the prevalence of adenomas and AAs in 40- to 49-year-old individuals undergoing screening colonoscopy because of a family history (FH) of polyps and to compare these data with those of a control population of similar age. DESIGN: Retrospective cross-sectional study. SETTING: Tertiary care academic medical center and Veterans Affairs medical center. PATIENTS: Study subjects included all 40- to 49-year-old asymptomatic individuals undergoing initial screening colonoscopy at our institution from January 1, 2006, to June 1, 2009, because of an FDR with polyps. The control population consisted of all 40- to 49-year-old individuals who underwent their first colonoscopy during the same period because of abdominal pain, diarrhea, or constipation without an FH of polyps or colorectal cancer. INTERVENTION: Colonoscopy. MAIN OUTCOME MEASUREMENTS: The prevalence of adenomas of any size, AAs, and risk factors associated with adenomas. RESULTS: The prevalence of adenomas was greater in the FH of polyps group (n = 176) compared with the control sample (n = 178) (26.7% vs 13.5%; P = .002) but was not statistically greater for AAs (5.7% vs 3.4%; P = .3). After adjusting for confounders, FH of a polyp was associated with an increased prevalence of adenomas (odds ratio 2.8 [95% CI, 1.4-5.5]). LIMITATIONS: Limited data on polyp histology in FDRs and limited sample size. CONCLUSIONS: Among 40- to 49-year-old patients undergoing screening colonoscopy because of an FDR with polyps, the prevalence of adenomas was greater than in a control population. Prospective research is needed to quantify the prevalence of AAs in this group and to determine whether these individuals should undergo screening colonoscopy at age 40. Copyright Â
BACKGROUND: Per current guidelines, patients with a first-degree relative (FDR) with adenomas should get screened at age 40. Data on the prevalence of adenomas and advanced adenomas (AAs) in these patients are lacking. OBJECTIVE: To examine the prevalence of adenomas and AAs in 40- to 49-year-old individuals undergoing screening colonoscopy because of a family history (FH) of polyps and to compare these data with those of a control population of similar age. DESIGN: Retrospective cross-sectional study. SETTING: Tertiary care academic medical center and Veterans Affairs medical center. PATIENTS: Study subjects included all 40- to 49-year-old asymptomatic individuals undergoing initial screening colonoscopy at our institution from January 1, 2006, to June 1, 2009, because of an FDR with polyps. The control population consisted of all 40- to 49-year-old individuals who underwent their first colonoscopy during the same period because of abdominal pain, diarrhea, or constipation without an FH of polyps or colorectal cancer. INTERVENTION: Colonoscopy. MAIN OUTCOME MEASUREMENTS: The prevalence of adenomas of any size, AAs, and risk factors associated with adenomas. RESULTS: The prevalence of adenomas was greater in the FH of polyps group (n = 176) compared with the control sample (n = 178) (26.7% vs 13.5%; P = .002) but was not statistically greater for AAs (5.7% vs 3.4%; P = .3). After adjusting for confounders, FH of a polyp was associated with an increased prevalence of adenomas (odds ratio 2.8 [95% CI, 1.4-5.5]). LIMITATIONS: Limited data on polyp histology in FDRs and limited sample size. CONCLUSIONS: Among 40- to 49-year-old patients undergoing screening colonoscopy because of an FDR with polyps, the prevalence of adenomas was greater than in a control population. Prospective research is needed to quantify the prevalence of AAs in this group and to determine whether these individuals should undergo screening colonoscopy at age 40. Copyright Â
Authors: Gregory L Austin; Jonathan I Goldstein; Stevany L Peters; Dennis J Ahnen Journal: Clin Gastroenterol Hepatol Date: 2011-01-14 Impact factor: 11.382
Authors: Kathryn L Lynch; Dennis J Ahnen; Tim Byers; David G Weiss; David A Lieberman Journal: Clin Gastroenterol Hepatol Date: 2003-03 Impact factor: 11.382
Authors: S J Winawer; A G Zauber; H Gerdes; M J O'Brien; L S Gottlieb; S S Sternberg; J H Bond; J D Waye; M Schapiro; J F Panish Journal: N Engl J Med Date: 1996-01-11 Impact factor: 91.245
Authors: Douglas K Rex; David A Johnson; Joseph C Anderson; Phillip S Schoenfeld; Carol A Burke; John M Inadomi Journal: Am J Gastroenterol Date: 2009-02-24 Impact factor: 10.864
Authors: H Ahsan; A I Neugut; G C Garbowski; J S Jacobson; K A Forde; M R Treat; J D Waye Journal: Ann Intern Med Date: 1998-06-01 Impact factor: 25.391
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer Journal: CA Cancer J Clin Date: 2008-03-05 Impact factor: 508.702
Authors: Lior Segev; Matthew F Kalady; Thomas Plesec; Eyal Mor; Gal Schtrechman; Aviram Nissan; James M Church Journal: Int J Colorectal Dis Date: 2020-01-13 Impact factor: 2.571
Authors: Antonio Picarelli; Marco Di Tola; Raffaele Borghini; Claudia Isonne; Annarita Saponara; Mariacatia Marino; Rossella Casale; Antonio Tiberti; Roberta Pica; Giuseppe Donato; Giuseppe Frieri; Enrico Corazziari Journal: J Clin Immunol Date: 2013-07-06 Impact factor: 8.317
Authors: Luiz Ronaldo Alberti; David Correa Alves De Lima; Kelly Cristine De Lacerda Rodrigues; Marcos Paulo Lima Taranto; Sergio Henrique Leão Gonçalves; Andy Petroianu Journal: Surg Endosc Date: 2012-05-02 Impact factor: 4.584
Authors: Hongha T Vu; Nneka Ufere; Yan Yan; Jean S Wang; Dayna S Early; Jill E Elwing Journal: World J Gastroenterol Date: 2014-06-14 Impact factor: 5.742
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059